223
Participants
Start Date
October 19, 2017
Primary Completion Date
February 22, 2022
Study Completion Date
January 4, 2023
Avelumab Phase 1b
Avelumab
Talazoparib Phase 1b
Talazoparib
Avelumab Phase 2
The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
Talazoparib Phase 2
The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
Institut Jules Bordet, Brussels
Cliniques Universitaires Saint-Luc, Brussels
Northern Cancer Institute, St Leonards
Northern Cancer Institute, Sydney
Phase 1 Unit, Department of Oncology, Section 5073., Copenhagen
Macquarie University, North Ryde
Herlev og Gentofte Hospital, Herlev
The Experimental Cancer Therapy Unit, Herlev
CRU Hungary Kft., Miskolc
Mater Misericordiae Ltd, Brisbane
Grand Hôpital de Charleroi - Site Notre-Dame, Charleroi
Fiona Stanley Hospital, Murdoch
NYU Investigational Pharmacy, New York
NYU Langone Medical Center, New York
NYU Langone Radiology, New York
NYU Laura and Isaac Perlmutter Cancer Center, New York
NYU Langone Radiology - Ambulatory Care Center, New York
Icahn School of Medicine at Mount Sinai, New York
Mount Sinai Hospital- Pharmacy department, New York
Roswell Park Cancer Center Institute, Buffalo
Georgetown University Medical Center, Washington D.C.
Gachon University Gil Medical Center, Incheon
Cleveland Clinic Taussig Cancer Center Investigational Pharmacy, Cleveland
Cleveland Clinic, Cleveland
University Of Minesota Health: Clinics And Surgery Center, Minneapolis
University of Minesota Medical Center, Fairview IDS Pharmacy, Minneapolis
University of Minnesota Medical Center, Fairview, Minneapolis
Highlands Oncology Group, Fayetteville
Highlands Oncology, Fayetteville
Highlands Oncology Group, Rogers
Highlands Oncology, Rogers
Highlands Oncology Group, Springdale
Highlands Oncology, Springdale
The University of Texas MD Anderson Cancer Center, Houston
Keck Hospital of USC, Los Angeles
LAC+USC Medical Center, Los Angeles
USC/Norris Comprehensive Cancer Center/Investigational Drug Services, Los Angeles
USC/Norris Comprehensive Cancer Center, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
Tower Hematology Oncology Medical Group, Beverly Hills
Hoag Memorial Hospital Presbyterian, Newport Beach
Freidenrich Center for Translational Research (CTRU), Palo Alto
Stanford Cancer Institute, Stanford
Stanford Hospital and Clinics, Stanford
Stanford Women's Cancer Center, Stanford
"FSBI National Medical Research Centre of Oncology n.a.", Moscow
"State budgetary institution of healthcare of Yaroslavl region Clinical oncology hospital", Yaroslavl
Medical Radiological Research Center n.a. A.F. Tsyba -, Obninsk
Medical Radiological Research Center n.a. A.F. Tsyba, Obninsk
GBUZ, Chelyabinsk
"Budget Healthcare Institution of Omsk Region Clinical Oncology Dispensary", Omsk
Massachusetts General Hospital (MGH), Boston
Massachusetts General Hospital Attn: Lalit Joshi, Boston
Massachusetts General Hospital Attn: Svetlana Rashkova, Boston
Brigham & Women's Hospital, Boston
Dana Farber Cancer Institute, Attn: Vasilika Koci, PharmD, Boston
Dana-Farber Cancer Institute, Boston
Cross Cancer Institute, Edmonton
Princess Margaret Cancer Centre, Toronto
Orszagos Onkologiai Intezet, Budapest
Pecsi Tudomanyegyetem, Pécs
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
University College London Hospitals NHS Foundation Trust, London
University Hospitals of Leicester NHS Trust, Leicester
Freeman Hospital, The Sir Bobby Robson Cancer Trials, Newcastle upon Tyne
Lead Sponsor
Pfizer
INDUSTRY